AMRUTANJANNSEAmrutanjan Health Care Limited· PharmaceuticalsHighNeutral
Announced Wed, 13 May · 11:59 IST

Amrutanjan Health Care Limited has informed the Exchange regarding 'Financial Results-Machine Readable Format'.

Revenue Growth 20pctPat Growth 25pctResults View source PDF

AMRUTANJAN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+3.1%1-day move
₹553.10
prior close
₹573.95
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.3+0.3-0.2-0.2+3.1+0.5+0.9-0.1-0.2+1.3-1.5+0.4-1.8
Up moveDown movePending
AI summary

Amrutanjan Health Care reported audited FY2025-26 results with standalone revenue of ₹50,255.27 lakh, up 11.2% from ₹45,181.63 lakh in the prior year. Profit after tax grew 13.9% to ₹5,791.78 lakh versus ₹5,083.47 lakh. The Board recommended a final dividend of ₹2.90 per share (₹289.11 lakh total). Exceptional items include a one-time ₹760.50 lakh provision for revised lease rent on Tamil Nadu leasehold land (lost in court) and ₹125.17 lakh impact from new labour codes. The Auditor (B S R & Co. LLP) issued an unmodified opinion with no qualifications. The company also appointed Mr. Ramaswami Krishnan as Independent Director and launched Phase 2 of its ESOP scheme.

Likely market impact

Revenue and profit grew double-digits year-on-year with healthy operating cash flow of ₹3,596.77 lakh. The exceptional items are non-recurring and do not undermine core business performance. The clean audit opinion and dividend declaration are positive signals for shareholders.